RAIN edema, defined as the abnormal increase in water content of the brain parenchyma, can increase ICP, potentially leading to ischemia, herniation, and death. Edema and elevated ICP are often treated with intravenous hyperosmotic agents to create an osmotic gradient to dehydrate cerebral structures. Mannitol is the osmotic diuretic most commonly used in the intensive care unit to reduce cerebral edema and brain swelling. In addition to its osmotic effect on astrocytes and neurons, it is thought to open the blood-brain barrier by shrinking endothelial cells and temporarily opening tight junctions. 22 Although it reduces brain volume by redistributing water from the intracellular to the intravascular space, the immediate effects on ICP reduction may be due to changes in the rheological characteristics of the blood. These changes include increased plasma volume; decreased hematocrit and viscosity; and increased CPP, cerebral blood flow, and cerebral oxygen delivery. These changes can lead to a vasoconstrictive response that decreases the intracranial blood volume with a concomitant decrease in ICP.
RAIN edema, defined as the abnormal increase in water content of the brain parenchyma, can increase ICP, potentially leading to ischemia, herniation, and death. Edema and elevated ICP are often treated with intravenous hyperosmotic agents to create an osmotic gradient to dehydrate cerebral structures. Mannitol is the osmotic diuretic most commonly used in the intensive care unit to reduce cerebral edema and brain swelling. In addition to its osmotic effect on astrocytes and neurons, it is thought to open the blood-brain barrier by shrinking endothelial cells and temporarily opening tight junctions. 22 Although it reduces brain volume by redistributing water from the intracellular to the intravascular space, the immediate effects on ICP reduction may be due to changes in the rheological characteristics of the blood. These changes include increased plasma volume; decreased hematocrit and viscosity; and increased CPP, cerebral blood flow, and cerebral oxygen delivery. These changes can lead to a vasoconstrictive response that decreases the intracranial blood volume with a concomitant decrease in ICP. 21 Despite the clinical importance of mannitol, current treatment protocols vary widely, and the precise effect of dose on ICP response is not known. The Brain Trauma Foundation has developed evidence-based guidelines for the treatment of traumatic brain injury in an attempt to decrease mortality and morbidity rates. Guidelines for the use of mannitol state that effective doses range from 0.25 to 1.0 g/kg body weight but that there are insufficient data to support a treatment standard. 4 A recent systematic review based on only seven trials, including three by Cruz et al., [6] [7] [8] concluded that high-dose mannitol up to 1.4 g/kg "may be preferable to conventional-dose mannitol in the acute management of comatose patients with severe head injury." 31 However, the studies by Cruz et al. and 3 of the other 4 studies in the systematic review report daily ICP averages, blood pressure change, 25 mortality rate or neurological outcome, 28 and number and duration of hypertensive episodes, 30 but no dose-response data. Despite insufficient data on the duration of mannitol's effect, timing of administration, or the mannitol dose-response curve, a number of Dose-response relationship of mannitol and intracranial pressure: a metaanalysis recent studies have compared the effects of mannitol with hypertonic saline, 2, 10, 12 glycerol, 3 hyperventilation, 29 and cerebrospinal fluid drainage. 15 Recent work by our group was, to our knowledge, the first to quantify a dose-dependent effect of mannitol on ICP reduction using data from high-frequency continuous physiological monitoring (unpublished data). The goal of this metaanalysis was to aggregate and analyze data from all studies that have quantitatively characterized the dose-response relationship between mannitol and ICP.
Clinical Material and Methods
We performed a PubMed search to identify studies in which the authors discussed both mannitol and ICP. We included in our analysis all studies that reported Ն 1 gross or weight-adjusted mannitol dose amount and either an initial and final ICP measurement or an absolute measure of ICP change. When available, we also captured information on the mannitol administration protocol, the number of patients studied, the time over which the ICP change was observed, the time at which minimum ICP was observed, and the duration of mannitol's effect. We captured other aspects of treatment when available. In cases in which results for multiple doses were reported for aggregate numbers of patients, we made no assumptions about breakdowns. When possible, we reported weight-adjusted dose (g/kg), gross dose (g), and mannitol amount (for example, 250 ml of 20% solution). When dosage was only reported as a gross amount, we converted it to a weight-adjusted amount for analysis, assuming a 70-kg person. We report ICP change in millimeters of mercury except for studies in which only the percentage of change was given. The number of significant figures for ICP data was preserved from the original studies; variance was not included in our analysis. Statistics are reported as the mean Ϯ standard deviation.
The metaanalysis was based on the data collection and transformation described earlier. We first performed simple, nonparametric analyses. Next, we developed a linear regression model using the data set compiled from the literature. We then compared ICP decrease between studies in which mannitol was given for ICP Ͼ 30 mm Hg and Ͻ 30 mm Hg. Finally, we performed nonlinear regression to fit the relationship between ICP decrease and time of ICP measurement. Regression and Student t-test analyses were performed using statistical software (SPSS version 13, SPSS, Inc.; and GraphPad Prism version 4.02, GraphPad Software, Inc.). In addition, to construct a picture of which studies have most significantly influenced mannitol dosing research and, potentially, clinical practice, we also determined citation frequencies for mannitol dose-response papers using the ISI Web of Science database (The Thomson Corp.).
Results
Of the 581 papers found in our literature search, the majority mention mannitol and ICP as just one of several interventions or outcomes of interest in humans and animals. We identified 18 studies that provided quantitative data on mannitol dose and/or ICP decrease in humans for 35 dose amounts (Table 1) . Of these 35 dose amounts, 26 included corresponding ICP response data ( Table 2 ). The mannitol administration protocol was usually reported as a duration during which ICP was higher than a certain threshold ( Table 3) . The time during which the ICP change was observed, the time at which minimum ICP was observed, and the duration of mannitol's effect were sometimes subject to interpretation or limited by the study design.
We examined several study design and outcome parameters ( Table 4 ). The protocols for administering mannitol showed minimal variation and were usually based on detection of ICP higher than a predetermined threshold (range 15-30 mm Hg) for a certain amount of time (range 3-10 minutes). Eight of the 18 studies set a threshold at 20 mm Hg. Because we were primarily concerned with dose response, we studied the other parameters of interest according to the 26 dose points we found in the literature rather than according to the 18 studies. There was significant variability in sample sizes. The median number of patients at each dose point was 9.5, whereas the range was from 1 to 158. Similarly, the median number of doses given at each dose point was 23, whereas the range was from 1 to 1932. Demographic data were sparse. Mean age was reported in 9 of the 18 studies and ranged from 27.9 to 60.3 years. The sex ratios were also reported in 9 studies and ranged from 33 to 100% male. The mean Glasgow Coma Scale score was reported in 6 studies and ranged from 5.1 to 7.7. Outcome data were more consistent. Initial ICP was 28.0 Ϯ 8.4 mm Hg, reduced ICP was 16.9 Ϯ 5.5 mm Hg, time at which ICP was measured was 38.5 Ϯ 22.5 minutes, time to ICP minimum was 60.9 Ϯ 33.1 minutes, and duration of effect was 180.2 Ϯ 72.0 minutes.
Many aspects of patient treatment reflected the evolution of clinical practice over time (Table 5 ). Steroid use was last reported in 1980, and barbiturate use was last reported in 1997. On the other hand, surgeries for decompression or lesion evacuation have been common since the mid-1990s, and use of pressors and CPP monitoring has been consistent since the study reported by Rosner et al. 23 in 1995. Other parameters (such as electrolytes, hematocrit, temperature, glucose, and hemoglobin) and interventions (for example, head elevation, hypothermia, cerebrospinal fluid drainage, and unspecified medications) are frequently but inconsistently reported. Obviously, these are critical parameters that greatly affect ICP. These various aspects of treatment indicate the complexity and variability in the clinical management protocols and the challenge in comparing dose response across studies.
We found that authors of most studies did not report Ն 1 of the parameters of interest; duration of mannitol's effect was most frequently unreported (Table 6 ). There were several other reporting ambiguities. In the study by Battison et al., 2 ICP was measured a median of 10 minutes before and 1 hour after mannitol doses. In the study by Fortune et al., 9 data were interpreted from a figure. Hartl et al. 11 only reported data for patients with ICP Ͼ 20 mm Hg. In the study by James, 14 the results excluded 6 doses that had less than a 10% effect. We retrospectively calculated ICP in the study by Kirkpatrick et al. 16 based on their reported percentage of decrease. In the study by Marshall et al., 17 which forms the basis of the current guidelines for mannitol dose, no patient received the same dose twice, but exact dose dis-tribution was not specified. McGraw et al. 18 reported data for a total of 150 patients, time intervals are reported for the whole sample, and decreases are interpreted from a figure. Muizelaar et al. 21 reported data separately for patients with intact versus defective autoregulation. Doses for Ware et al. 32 were calculated based on their detailed table.
Even with simple, nonparametric analysis, the dose-response data in the literature are inconclusive. All 18 studies and 34 of 35 dose amounts showed that mannitol reduces ICP. However, of 18 published studies, only 4 included data on multiple dose amounts. Of those 4, 2 (those by McGraw et al. 18 and James
13
) showed that ICP decrease is greater for higher doses of mannitol. Marshall and colleagues 17 reported mixed results for different doses of mannitol, and the study by Ware et al. 32 shows an inverse relationship. There are caveats though. The study by James 13 only reported the percentage of decrease, and that by Ware et al. was a pilot study in which the authors examined the effect of hypertonic saline (23.4%) and included only patients who did not respond to repeated doses of mannitol.
Furthermore, data for the lowest dose amount in the Ware et al. study all came from 1 patient.
Based on our review of the literature and data, we constructed a dose-response model. The linear relationship we found (⌬ICP = 6.6 ϫ dose Ϫ 1.1) (Fig. 1 left) , where ⌬ICP signifies the change in ICP, did not achieve statistical significance (p = 0.27). The low R-square value of 0.05 could reflect the variation in protocols among studies or the variation in patients both within and among studies. When we separated the data by initial ICP (Fig. 1 right) and repeated the regression, we found similar, weak linear relationships, particularly after treating the highest dose in When we analyzed the decrease in ICP by initial ICP, we saw that ICP decrease was significantly greater when initial ICP was Ͼ 30 mm Hg than when the initial ICP was Ͻ 30 mm Hg (23.2 Ϯ 6.1 mm Hg compared with 6.8 Ϯ 4.5 mm Hg; p Ͻ 0.001) (Fig. 2 left) . This was true regardless of dose (Fig. 2 right) . We did not see dose-dependent or ICP- dependent relationships for duration of effect or time to minimum ICP, although these data were more sparsely and ambiguously reported. Finally, we analyzed ICP decrease by the time at which ICP was measured and found that decrease is greatest shortly after a mannitol dose (Fig. 3) . The nonlinear regression second-order polynomial curve (⌬ICP = 47.2 Ϫ 2.0 ϫ time ϩ 0.02 ϫ time ) is excluded as an outlier. We interpret the upward trend (that is, greater ICP decrease) at the later time points to be a potential artifact of the data.
Of note, several important studies, including the large studies by James 14 infrequently cited compared with other contemporary studies according to the ISI Web of Science database (Table  7) . On the other hand, the paper by Rosner et al. 23 is cited frequently, due in part to its influential ideas on the study of CPP-based therapy in addition to its mannitol and ICP results. Likewise, the often-cited study by Muizelaar et al. 20 includes discussion of measurement of cerebral blood flow and testing of autoregulation.
Discussion
After decades of work, it is surprising that a dose-response curve for mannitol has not been determined, particularly given that it is one of the few agents used to treat elevated ICP. Although many individual studies have shown that mannitol decreases ICP, taken together, the data from our nonparametric analysis of the literature and the wide 95% confidence interval in the dose-response meta-regression suggest that varying dosage has an undefined effect on decrease in ICP. In fact, the literature suggests that ICP decrease depends more strongly on mannitol's administration protocol-specifically the ICP level at the time the dose is given-than on dose. Although contemporary studies may demonstrate a more complete understanding of physiology and molecular biology, they sometimes lack the large patient sample sizes and quantitative models of earlier studies. Moreover, recent studies in which the authors have compared the effects of other ICP treatments with mannitol are doing so without complete knowledge of mannitol's dose-and time-dependent effects. More comprehensive studies are needed to definitively address the question of mannitol dose response. These studies could further elucidate the relationships among parameters related to ICP management, enable more precise use of mannitol, and improve patient outcomes.
A Chronological Review
Mannitol dose-response studies in the 1970s and 1980s were often large and followed mannitol administration protocols requiring ICP of Ͼ 25 mm Hg. These included 2 studies each by James and colleagues 13, 14 and McGraw and colleagues 18, 19 containing 48, 60, 150, and 61 patients. James 13 measured a peak ICP reduction at 44 minutes but saw no relationship between dose and rapidity of peak response. This author also reported that return to baseline ICP was unpredictable but related to the initial ICP and that doses Ͻ 1 g/kg did not always reduce ICP. McGraw and colleagues 18, 19 found that the level of ICP and the cumulative amount of preceding doses of mannitol influenced the response of ICP more than the dose of mannitol. They concluded that unnecessarily large doses or prophylactic doses could lead to more mannitol being required later. Marshall et al. 17 found that "smaller doses than those previously recommended were effective in reducing the ICP acutely." Several studies have been conducted since 1990. Authors of these studies have lowered the minimum ICP threshold for mannitol administration, perhaps reflecting studies showing that even ICP Ͼ 15 mm Hg can result in herniation. 1 Overall, reporting of relevant dose response parameters has been more complete, with the exception of time to achieve minimum ICP. Clearly, the duration of the mannitol effect is critical when comparing doses or other ICP treatments. Furthermore, these studies have typically included fewer patients, with the exception of Cruz et al., [6] [7] [8] who studied preoperative high-dose mannitol but only reported daily average values, and Rosner et al. 23 who focused primarily on CPP management. Of note, Hartl et al. 11 found that when initial ICP was Ͻ 20 mm Hg, ICP did not change significantly during or after mannitol infusion, but with a preinfusion ICP Ͼ 20 mm Hg, a decrease was seen.
Challenges and Next Steps
There are several challenges to constructing an ideal dose-response curve, as is commonly done in pharmacodynamic studies, based on retrospective clinical data. For example, mannitol doses are administered according to patient need, often as gross rather than weight-adjusted amounts, and doses at the low and high ends of the range may not be administered because they are either not efficacious or may have adverse effects. High doses of mannitol increase serum osmolality and have been associated with risk of renal failure. 5 Also, height measurements needed to calculate ideal body weight are never reported. It is possible that some ICP readings captured particularly volatile periods or were incorrectly recorded given the low-resolution data collection tools that exist even today. Finally, it is clear that treatment protocols varied significantly among centers and over time, particularly given that this metaanalysis includes stroke and tumor patients as well as heterogeneous samples of patients with traumatic brain injury.
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Well-designed, adequately-funded studies in which the authors record and report a broad set of data (gross dose amounts; time, sequence, duration, and interval of dose administration; physiological parameters such as ICP and CPP; metabolic markers such as osmolality and creatinine; and detailed patient characteristics such as age, race, sex, weight, Glasgow Coma Scale score, and so on) will be crucial in defining the mannitol-ICP dose-response relationship and could also enable better future metaanalysis. For example, the McGraw and Howard 19 model, ⌬ICP = 9.7 Ϫ 0.03 ϫ dose Ϫ 0.40 ϫ initial ICP ϩ 0.02 ϫ drug in previous 3 hours, only accounts for 35% of the variation in ICP, but it presents a precise quantitative framework for addressing the question. Comprehensive mathematical models based on continuously monitored physiological parameters are needed to elucidate the relationships between the treatments, vital signs, and outcomes in clinical care.
Conclusions
Mannitol is the osmotic agent most commonly used to reduce brain mass after brain injury and stroke, yet its pharmacodynamics are still not understood. In fact, in sharp contrast with most other drugs used to treat common diseases (hypertension, diabetes, and so on), protocols such as dosage regimens and thresholds for treatment still vary widely. This metaanalysis aggregated data from studies that have quantitatively characterized the dose-response relationship for mannitol and ICP. Our nonparametric analysis revealed that, although mannitol is always shown to reduce ICP, the quantitative relationship between dose and response is inconsistent. We found a weak linear relationship between change in ICP and mannitol dose (⌬ICP = 6.6 ϫ dose Ϫ 1.1; p = 0.27, R 2 = 0.05). The lack of statistical significance and low R-square value could reflect the variation in protocols among studies or the variation in patients both within and among studies. However, we saw a strong relationship between ICP decrease and ICP levels at the time mannitol was given. Furthermore, ICP decreases were greatest shortly after doses were given, but there are limited data to support this conclusion. We also found that recent studies tend to enroll fewer patients and set a lower ICP threshold for mannitol administration but are more complete in their reporting of parameters of interest.
Surprisingly, after years of use, the nature of the mannitol dose-response curve is still under debate. Moreover, studies in which authors compare the effects of new ICP treatments with mannitol are undertaken with incomplete knowledge of mannitol's effects and therefore risk drawing misleading conclusions. It is difficult to imagine reducing the variability in the clinical management of elevated ICP without fully understanding these fundamental pharmacodynamic relationships. The metaanalysis presented here highlights the need for a consensus of methods and results required to determine this relationship. It also underscores the urgent need for well-funded, definitive studies. 
